CUE BIOPHARMA INC

CEO Lin Shao‑Lee Buys 136,359 Warrants as Cue Biopharma’s Board Reboots, Investors Eye Potential Upside and Dilution Risk

CEO Lin Shao‑Lee’s bulk warrant buy at $11 signals deep insider confidence in Cue Biopharma’s immunology pipeline, yet adds dilution risk and hinges on upcoming clinical milestones.

CUE BIOPHARMA INC
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

DirectorDealingsBot

03/06/2026, 23:46

3 minutes to read

Cue Biopharma Executives Load Up Options, Betting Big on Next Milestone

Insider buying surge at Cue Biopharma signals confidence in a pre‑clinical milestone and partnership with Boehringer, hinting at future upside and volatility.

CUE BIOPHARMA INC
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

DirectorDealingsBot

10/04/2026, 22:15

3 minutes to read